ETP46464

Research use only, not for human use.

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

ETP-46464 (ATRi) also inhibits DNA-PK, PI3Kα and ATM with IC50s of 36 nM, 170 nM and 545 nM, respectively. Platinum-sensitive and -resistant ovarian, endometrial and cervical cancer cell lines are treated with varying levels of Cisplatin (0-50 μM) with or without the ETP-46464 (5.0 μM) and/or the KU55933 (10.0 μM) for 72 h. Single-agent dose response analyses of ETP-46464 and KU55933 in a subset of cell lines reveal a wide LD50 range of 10.0±8.7 and 38.3±7.6 μM respectively. Co-treatment doses are chosen based on these studies and previously published evidence of phospho-Chk1 (Ser345) and phospho-ATM (Ser1981) inhibition following ionizing radiation exposure and dose response treatments with ETP-46464 and KU55933. Treatment with ETP-46464 significantly increases the response of Cisplatin in all cell lines tested, resulting in 52-89% enhancement in activity and are synergistic. The combined inhibition of ATR and ATM enhances the response of Cisplatin to a level equivalent to that observed using ETP-46464 alone. These effects are independent of p53 status, and are observed in all gynecologic (GYN) cancer cells tested. Treatment with ETP-46464, but not KU55933, not only sensitizes these GYN cancer cell lines to Cisplatin, but also enhances the response of Carboplatin.

——

ATM Inhibitor III | ATR Inhibitor III

Cell Cycle/DNA Damage

ATM/ATR

ATM| ATR| DNA-PK| mTOR| PI3Kα

Cancer

——

1345675-02-6

470.52

C30H22N4O2

>98% (HPLC)

DMSO: 6 mg/mL (12.75 mM)

N#CC(C)(C)C1=CC=C(N(C2=C3C=NC4=CC=C(C5=CC6=CC=CC=C6N=C5)C=C24)C(OC3)=O)C=C1

α,α-dimethyl-4-[2-oxo-9-(3-quinolinyl)-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl]-benzeneacetonitrile

(-20℃)

With Ice Pack

≥ 2 years